¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"potential tumor doubling time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® coagulation time ÇÑ±Û ÀÀ°í½Ã°£
¼³¸í   
  Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò¶õ ¹°ÁúÀº ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹­´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼­ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. Ç÷¾×ÀÀ°í´Â ´ÙÀ½°ú °°Àº 3´Ü°è·Î ÀÌ·ç¾îÁø´Ù.
  
  Ã¹¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼­ prothrombin activator¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ prothrombin activator¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ Ç÷¾×¼Ó¿¡ Àִ ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù.
  
  ÀÀ°íÀÛ¿ëÀº Å©°Ô 2°¡Áö·Î ³ª´µ´Âµ¥, ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ°¡ ±×°ÍÀÌ´Ù. ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀڴ °¢±â º°°³·Î ÀÛ¿ëÇÏÁö¸¸, °á±¹Àº ¸¶Áö¸· °úÁ¤¿¡¼­ Çϳª·Î ¸¸³ª¼­ ¼¶À¯¼Ò¿øÀ» ¼¶À¯¼Ò(ÀÀ°íÀÛ¿ëÀÇ ¸¶Áö¸· ´Ü°è¿¡ »ý¼ºµÇ¸ç ´Ü´ÜÇϰí Ç®¸®Áö ¾Ê´Â ¸ÅµìÀ» Çü¼ºÇÏ¿© ÁöÇ÷ÀÛ¿ëÀ» ¿Ï¼ºÇÑ´Ù)À¸·Î ¸¸µé¾î ÀÀ°íÀÛ¿ëÀ» ³ªÅ¸³½´Ù.
¿µ¹® bleeding time ÇÑ±Û ÃâÇ÷½Ã°£
¼³¸í   
  ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖ¾úÀ» °æ¿ì¿¡ Çǰ¡ ¸Ü´Âµ¥ ±îÁö °É¸®´Â ½Ã°£À» ÃâÇ÷½Ã°£À̶ó°í ÇÑ´Ù. »ç¶÷ÀÇ ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡ À̰ÍÀ» ¸·°í ÇǸ¦ ´õÀ̻󠳪Áö ¾Ê°Ô Çϴ °ÍÀ» ÁöÇ÷À̶ó°í ÇÑ´Ù. ÁöÇ÷ÀÇ °úÁ¤¿¡´Â Å©°Ô µÎ °¡Áö ´Ü°è°¡ ÀÖ´Ù. Ã¹¹øÂ° ´Ü°è´Â Ç÷¼ÒÆÇµéÀÌ »óó°¡ ³ª¼­ ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¸¦ ¸·´Â °ÍÀÌ´Ù. ÀÌ·¸°Ô Çϸ頿켱 Ç÷°üÀÇ ¼Õ»óºÎÀ§·ÎºÎÅÍ Çǰ¡ ³ª¿À´Â °ÍÀ» ¸·À» ¼ö°¡ ÀÖ´Ù. ´ÙÀ½ÀÇ ´Ü°è´Â »ó󸦠¸·°í Àִ Ç÷¼ÒÆÇÀ§¿¡ ¿©·¯ °¡Áö ¹°ÁúµéÀÌ ÀÛ¿ëÇØ¼­ ´õ¿í ´Ü´ÜÇϰԠÇÏ¿© »óó°¡ ³­ Ç÷°ü¿¡¼­ Çǰ¡ »õ´Â °ÍÀ» ¿µ±¸È÷ ¸·´Â °ÍÀÌ´Ù. ½±°Ô ¸»Çϸé Ç÷¼ÒÆÇÀº º®µ¹¿¡ ÇØ´çÇϴ °ÍÀÌ°í µÎ¹øÂ° °úÁ¤¿¡ Âü¿©Çϴ ¹°ÁúµéÀº ½Ã¸àÆ®¿¡ ÇØ´çÇϴ °ÍÀÌ´Ù. ÀÌ µÎ °úÁ¤ÀÌ ¿ÏÀüÇÒ °æ¿ì¿¡ ÁöÇ÷ÀÌ ¼øÁ¶·Ó°Ô ÀϾ´Ù.
  
  ÃâÇ÷½Ã°£Àº À§¿¡¼­ ¼³¸íÇÑ ÁöÇ÷ÀÇ µÎ°¡Áö °úÁ¤ Áß¿¡¼­ Ã¹¹øÂ° °úÁ¤¿¡ ÀÇÇØ¼­¸¸ ¿µÇâÀ» ¹Þ´Â´Ù. Áï ¼Õ»óµÈ Ç÷°üÀ» ¸·¾ÆÁִ º®µ¹¿¡ ÇØ´çÇϴ Ç÷¼ÒÆÇÀÇ ±â´É¸¸ Á¤»óÀÏ °æ¿ì¿¡ ÃâÇ÷½Ã°£Àº Á¤»óÀ¸·Î ³ª¿Â´Ù. ¸¸¾à Ç÷¼ÒÆÇÀÇ ±â´É¿¡ ÀÌ»óÀÌ Àִ °æ¿ì¿¡´Â ÀÚ¿¬È÷ ÃâÇ÷½Ã°£ÀÌ ±æ¾îÁø´Ù.
¿µ¹® prothrombin time ÇÑ±Û ÇÁ·ÎÆ®·Òºó½Ã°£
¼³¸í   
  ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼­ ÇÕ¼ºµÇ´Â ºñŸ¹Î K ÀÇÁ¸¼º ÀÀ°í´Ü¹éÁúÀÇ ÇϳªÀ̸ç, ÇÁ·ÎÆ®·Òºó½Ã°£Àº ¿ÜÀΰè ÀÀ°íȰ¼ºÀ» Á¾ÇÕÀûÀ¸·Î Æ¯Á¤Çϴ °Ë»çÀÇ ÇϳªÀÌ´Ù. ÇǰËÇ÷Àå¿¡ Ä®½·À̿°ú Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾(Á¦III ÀÀ°íÀÎÀÚ)À» °¡ÇØ, ¼¶À¯¼Ò°¡ ³ªÅ¸³¯ ¶§±îÁöÀÇ ½Ã°£À¸ ÃøÁ¤ÇÑ´Ù.
¿µ¹® solid tumor ÇÑ±Û °íÇüÁ¾¾ç
¼³¸í   
  ¼¼Æ÷·Î ²Ë Âù Á¾¾çÀ» ¸»ÇÔ. ¹éÇ÷º´ µîÀÇ Ç÷¾×¾Ï°ú °°ÀÌ ÇüŸ¦ ÃëÇÏÁö ¾Ê°í ¾×üÀΠ»óÅÂÀÇ ¾Ï°ú ´ëÁ¶µÇ´Â ¿ë¾î·Î¼­ ´Ü´ÜÇÑ µ¢¾î¸®·Î ±¸¼ºµÈ ¾Ç¼ºÁ¾¾çÀÌ´Ù. ´ëºÎºÐÀÇ Á¾¾çÀÌ ÀÌ¿¡ ÇØ´çÇÑ´Ù. Æ¯È÷ Ç¥ÇÇÁ¶Á÷¿¡¼­ ±â¿øÇÑ Á¾¾çÀ» ¸»ÇÑ´Ù.
¿µ¹® ulcerating tumor ÇÑ±Û ±Ë¾ç¼º Á¾¾ç
¼³¸í   
  Á¾¾çÀǠǥ¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇϴ °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼­ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇϴ °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿­À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • doubling dose
    ¹è°¡¼±·®
  • adenomatoid odontogenic tumor
    »ùÁ¾¸ð¾çÄ¡¿ø¼ºÁ¾¾ç
  • adenomatoid tumor
    »ùÁ¾¸ð¾çÁ¾¾ç
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • collision tumor
    Ãæµ¹Á¾¾ç
  • carcinoid tumor
    Ä«¸£½Ã³ëÀ̵åÁ¾¾ç
  • cystic tumor
    ³¶¼ºÁ¾¾ç
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
  • Ewing¡¯s tumor
    À¯À×Á¾¾ç
  • embryonal tumor
    ¹è¾Æ¼ºÁ¾¾ç
  • endodermal sinus tumor
    ³»¹è¿±±¼Á¾¾ç, ³»¹è¿±µ¿Á¾¾ç
  • fecal tumor
    ´ëº¯µ¢ÀÌ, ºÐÁ¾(ÝÐðþ)
  • gastrointestinal autonomic nerve tumor
    À§Ã¢ÀÚÀÚÀ²½Å°æÁ¾¾ç, À§Àå°üÀÚÀ²½Å°æÁ¾¾ç
  • gastrointestinal stromal tumor
    À§Ã¢ÀÚ±âÁúÁ¾¾ç, À§Àå°ü±âÁúÁ¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • sex cord-stromal tumor tumor
    ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • potential difference
    Àü¾ÐÂ÷, ÀüÀ§Â÷
  • potential gradient
    ÀüÀ§±â¿ï±â, ÀüÀ§Â÷
  • potential
    ÀüÀ§, °¡´É¼º, ÀáÀç·Â
  • action potential
    Ȱµ¿ÀüÀ§
  • auditory evoked potential
    µè±âÀ¯¹ßÀüÀ§, û°¢À¯¹ßÀüÀ§
  • cortical evoked potential
    °ÑÁúÀ¯¹ßÀüÀ§, ÇÇÁúÀ¯¹ßÀüÀ§
  • evoked potential
    À¯¹ßÀüÀ§
  • membrane potential
    ¸·ÀüÀ§
  • reversal potential
    ¿ªÀüÀüÀ§, ¿ªÀüÀü¾Ð
  • transmembrane potential
    ¸·ÀüÀ§, ¸·Àü¾Ð
  • potential surface
    ÀüÀ§¸é
  • time
    ½Ã°£
  • acquisition time
    ȹµæ½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • doubling dose
    ¹è°¡¼±·®
  • adenomatoid tumor
    »ù¸ð¾çÁ¾¾ç, »ùÁ¾´àÀºÁ¾¾ç
  • adenomatoid odontogenic tumor
    »ù¸ð¾çÄ¡¾ÆÅ¿Á¾¾ç, »ù¸ð¾çÄ¡¾Æ¿øÀÎÁ¾¾ç
  • adrenal rest tumor
    ºÎ½ÅÀÜ·ùÁ¾¾ç
  • tumor antigen
    Á¾¾çÇ׿ø
  • tumor bearing animal
    Á¾¾çµ¿¹°
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • blue tumor
    û»öÁ¾
  • carcinoid tumor
    Ä«¸£½Ã³ëÀ̵åÁ¾¾ç
  • tumor control
    Á¾¾ç¾ïÁ¦
  • tumor lymphnode metastasis classification
    Á¾¾ç¸²ÇÁÀýÀüÀ̺зù
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
  • tumor embolism
    Á¾¾ç»öÀüÁõ
  • fecal tumor
    (¢¡stercoroma) ´ëº¯µ¢ÀÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • generation time =doubling t.
    ¼¼´ë½Ã°£(á¦ÓÛãÁÊà), ¹èÀ§½Ã°£(ÛÃêÈãÁÊà), ¼¼´ë±â(á¦ÓÛÑ¢).
  • EP =endocochlear potential
    ¿Í¿ì³»(Á÷·ù)ÀüÀ§
  • EPSP (excitatory postsynaptic potential)
    ÈïºÐ¼º(ýéÝÇàõ)½Ã³³½ºÈÄ(ý­)ÀüÀ§(ï³êÈ), ÈïºÐ¼º ¿¬Á¢(Ö§ïÈ)ÀüÀ§
  • Generator potential
    ±âµ¿ÀüÀ§(ÑÃÔÑï³êÈ)
  • IPSP = inhibitory postsynaptic potential
    ¾ïÁ¦¼º(åäð¤àõ)½Ã³À½ºÈÄ(ý­)Àü¾Ð(ï³äâ)
  • Intraneuronal potential
    ½Å°æ³»ÀüÀ§(ãêÌèÒ®ï³êÈ)
  • Junctional potential
    Á¢ÇÕºÎÀüÀ§(ïÈùêݬï³êÈ)
  • Local potential
    ±¹¼ÒÀüÀ§(ÏÑá¶ï³êÈ)
  • MEPP=>miniature end plate potential
    ¹Ì¼¼Á¾ÆÇÀü¾Ð
  • MEPP=£¾miniature end plate potential
    ¹Ì¼¼Á¾ÆÇÀüÀ§.
  • RP=£¾resting potential
    Á¤ÁöÀüÀ§.
  • Reinkes potential space
    ¶óÀÎÄÉ Àẹ°­
  • SEP, Somatosensory evoked potential
    ü¼º°¨°¢À¯¹ßÀüÀ§
  • absolute potential
    Àý´ëÀü¾Ð(¡­ï³äâ).³»°úÀý´ëÀüÀ§.
  • action potential
    Ȱµ¿ÀüÀ§(¡­ï³êÈ), Ȱµ¿Àü¾Ð(¡­ï³äâ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potential tumor doubling time
    ÀáÀçÁ¾¾ç¹è°¡½Ã°£
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • potential doubling time (Tpot)
    ÀáÀç¹è°¡½Ã°£
  • doubling time
    ¹è°¡½Ã°£
  • doubling time
    ¹è°¡ ½Ã°£
  • doubling time
    ¹è°¡½Ã°£(ÛÃÊ¥ãÁÊà).
  • generation time =doubling t.
    ¼¼´ë½Ã°£(á¦ÓÛãÁÊà), ¹èÀ§½Ã°£(ÛÃêÈãÁÊà), ¼¼´ë±â(á¦ÓÛÑ¢).
  • dilution, doubling
    µÎ¹è°è´ÜÈñ¼®¹ý
  • doubling
    ¹è°¡(ÛÃÊ¥), ÀÌÁß(ì£ñì).
  • doubling dilution
    2¹èÈñ¼®¹ý.
  • doubling dose
    ¹è°¡¼±·®(ÛÃÊ¥àÊåÖ).
  • brain tumor =cerebral tumor
    ½Å ¿Ü ³úÁ¾¾ç(ÒàðþåË).
  • superior sulcus tumor(carcinoma)=pancoast tumor
    »ó±¸¾ÏÁ¾
  • trichilemmal tumor => pilar tumor
  • tumor albus =white tumor ³ª
    ¹éÁ¾(ÛÜðþ)
  • absolute potential
    Àý´ëÀü¾Ð(¡­ï³äâ).³»°úÀý´ëÀüÀ§.
  • action potential
    Ȱµ¿ÀüÀ§(¡­ï³êÈ), Ȱµ¿Àü¾Ð(¡­ï³äâ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Deficiency (Monstrous tumor)
    °áÇÌ (±«¹°Á¾)
    [¿¾ ¿ë¾î] °áÇÌ
  • Monstrous tumor
    ±«¹°Á¾
    [¿¾ ¿ë¾î] ±«¹°Á¾
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ectopic tumor
    ÀÌ¼Ò Á¾¾ç(ì¶á¶ðþåË)
  • Ehrlich ascites tumor
    ¿¡¸¦¸®È÷ º¹¼öÁ¾(ÜÙâ©ðþ)
  • primary tumor
    ¿ø¹ß¼º Á¾¾ç(ê«Û¡àõðþåË)
  • tumor angiogenesis facotr
    Á¾¾ç Ç÷°üÇü¼ºÀÎÀÚ(ðþåËúìηû¡à÷ì×í­)
  • tumor antigen
    Á¾¾çÇ׿ø(ðþåËù÷ê«)
  • tumor initiator
    Á¾¾ç °³½ÃÀÚ(ðþåËËÒã·í­)
  • tumor necrosis factor
    Á¾¾ç ±«»çÀÎÀÚ(ðþåËÎÕÞÝì×í­)
  • tumor progression
    Á¾¾çÁøÇà(ðþåËòäú¼)
  • tumor promoter
    Á¾¾çÃËÁøÀÚ(ðþåËõµòäí­)
  • tumor-specific transplantation antigen
    Á¾¾çƯÀÌ ÀÌ½Ä Ç׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«)
  • tumor virus
    Á¾¾ç(ðþåË)¹ÙÀÌ·¯½º
  • assimilation time
    µ¿È­ÀÛ¿ë ½Ã°£ (ÔÒûùíÂéÄãÁÊà)
  • clotting time
    ÀÀ°í½Ã°£(ëêͳãÁÊà)
  • coincidence time
    µ¿½Ã½Ã°£(ÔÒãÁãÁÊà)
  • double beam in time spectrophotometer
    ½Ö±¤¼Ó ½Ã°£ ºÐ±¤±¤µµ°è(äªÎÃãÁÊàáÜÝÂÎÃÎÃÓøÍª)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • doubling time
    ¹è°¡½Ã°£
  • complex potential
    º¹ÇÕÀüÀ§
  • electrical potential
    ˟ˤ
  • electrostatic potential
    Á¤Àü±âÀü·ù
  • evoked potential
    À¯¹ßÀüÀ§
  • magnetic potential
    ÀÚ±âÆ÷ÅÙ¼È
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • brown tumor
    °¥»öÁ¾¾ç
  • carotid body tumor
    °æµ¿¸Æ¼ÒüÁ¾¾ç
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç
  • glomus jugulare tumor
    °æÁ¤¸Æ±¸Á¾¾ç
  • glomus tumor
    »ç±¸Á¾¾ç, ±Û·Î¹«½ºÁ¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • hormone dependent tumor
    È£¸£¸óÀÇÁ¸¼ºÁ¾¾ç
  • hormone producing tumor
    È£¸£¸ó»ý»êÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
TDT terminal deoxynucleotidyltransferase; thermal death time; tone decay test; tumor doubling time
TT tablet triturate; tactile tension; tendon transfer; test tube; testicular torsion; tetanus toxin; te...
PTT partial thromboplastin time; particle transport time; posterior tibial tendon (transfer); prothrombi...
MPD main pancreatic duct; maximum permissible dose; mean population doubling; membrane potential differe...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
T(pot) The potential doubling time
TDT Tumor doubling time
Td Tumor doubling time
LDT Lymphocyte doubling time
VDT volume doubling time
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • doubling time
    ¹è°¡ ½Ã°£
  • doubling dilution
    À̹è Èñ¼®¹ý
  • absolute potential
    Àý´ë Àü¾Ð, Àý´ë ÀüÀ§
  • action potential
    Ȱµ¿ ÀüÀ§, Ȱµ¿ Àü¾Ð
    ±ÙÀ°¼¼Æ÷ ¶Ç´Â ½Å°æ¼¼Æ÷°¡ ÈïºÐÇÒ ¶§ »ý±â´Â Àü±âÀû Ȱ¼ºÀ¸·Î¼­, Àü±âÀû, È­ÇÐÀû, ±â°èÀû ÀÚ±Ø ¹× ¿Âµµº¯È­ µî¿¡ ÀÇÇÏ¿© »ý±ä´Ù°í »ý°¢Çϰí ÀÖ´Ù.
  • adaptive potential
    ÀûÀÀ ÀáÀç·Â
    µ¿ÀǾî=ada
  • after-potential
    ÈÄ ÀüÀ§ Çö»ó
    ½ºÆÄÀÌÅ© ÀüÀ§ µÚ¿¡ º¼ ¼ö ÀÖ´Â ÀüÀ§ º¯µ¿ÀÌ´Ù. À½¼º ÈÄ ÀüÀ§¿Í ¾ç¼º ÈÄ ÀüÀ§·Î ³ª´¶´Ù. ÀüÀÚ´Â ¿ªÄ¡ÀÇ »ó½Â, ÈÄÀÚ´Â Çϰ­À» ÀÏÀ¸Å²´Ù.
  • body surface potential mapping
    üǥ¸é ÀüÀ§µµ
  • chemical potential
    È­ÇÐ ÀüÀ§, È­ÇÐ Æ÷ÅÙ¼³
  • compound action potential
    º¹ÇÕ È°µ¿ Àü¾Ð
  • contact potential difference
    Á¢ÃË ÀüÀ§Â÷
  • disability potential
    Àå¾ÖÀÇ ÀáÀ缺
  • dorsal root potential
    Èı٠Àü¾Ð
  • electric potential difference
    Àü¾Ð ÀüÀ§Â÷
  • electrical potential
    Àü±â·Â, ÀüÀ§
    1. Àü±âÀåÀ» ¸Å°³·Î ÇÏ¿© Á¤ÁöÇÑ ÀüÇÏ¿¡ ÀÛ¿ëÇÏ´Â Èû. 2. ¾î´À ÇÑ Á¡¿¡¼­ Àü±âÀû ÀÛ¿ëÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ¿¡³ÊÁöÀÇ ¾ç.
  • electrochemical potential
    Àü±â È­ÇÐ ÀüÀ§
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
doubling time <cell biology> The time taken for a cell to complete the cell cycle.
(10 Oct 1997)
tumor 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant.
2. Swelling, one of the cardinal signs of inflammations, morbid enlargement.
Origin: L. Tumere = to swell
(12 May 1997)
tumor marker <investigation, oncology> A substance in the body that usually indicates the presence of cancer.
These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples.
Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH).
They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
(18 Jul 2002)
tumor necrosis factor <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin.
Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine.
Synonym: cachectin.
Acronym: TNF
(13 Nov 1997)
action potential <physiology> The sequential, electrochemical polarization and depolarisation that travels across the membrane of a nerve cell (neuron) in response to stimulation (touch, pain, cold, etc.)
(09 Oct 1997)
bioelectric potential Electrical potential's occurring in living organisms.
(05 Mar 2000)
biological hazard potential <radiobiology> Measure of the hazard posed by a given quantity of radioactive material in which the variation in biological effects of the various elements are accounted for.
See: integrated biological hazard potential.
(21 Mar 1998)
biotic potential <biology, ecology> The potential growth a population of living things can expect if it were living under ideal environmental circumstances.
(19 Jan 1998)
body surface potential mapping Recording of regional electrophysiological information by analysis of surface potentials to give a complete picture of the effects of the currents from the heart on the body surface. It has been applied to the diagnosis of old inferior myocardial infarction, localization of the bypass pathway in wolff-parkinson-white syndrome, recognition of ventricular hypertrophy, estimation of the size of a myocardial infarct, and the effects of different interventions designed to reduce infarct size. The limiting factor at present is the complexity of the recording and analysis, which requires 100 or more electrodes, sophisticated instrumentation, and dedicated personnel.
(12 Dec 1998)
brain potential <physiology> The electrical charge of the brain as compared to a point on the body; the potential may be steady (DC potential) or may fluctuate at specific frequencies when recorded against time, giving rise to the electroencephalogram.
(05 Mar 2000)
pacemaker potential The voltage inscribed by impulses from an artificial electronic pacemaker.
(05 Mar 2000)
generator potential Local depolarisation of the membrane potential at the end of a sensory neurone in graded response to the strength of a stimulus applied to the associated receptor organ, e.g., a pacinian corpuscle; if the generator potential becomes large enough (because the stimulus is at least of threshold strength), it causes excitation at the nearest node of Ranvier and a propagated action potential.
(05 Mar 2000)
receptor potential The transmembrane potential difference of a sensory cell. Such cells are not generally excitable, but their response to stimulation is a gradual change in their resting potential.
(18 Nov 1997)
redox potential <chemistry> The reducing/oxidizing power of a system measured by the potential at a hydrogen electrode.
(18 Nov 1997)
reduction potential The inherent tendency of a compound to act as an electron donor or an electron acceptor. Measured in volts.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • doubling
    ¹è°¡;¹èÁõ;ÀÌÁßÀ¸·Î Çϱâ;Á¢¾î ³Ö±â
  • tumor
    Á¾±â
  • tumor
    Á¾Ã¢;ºÎ±â;Á¾±â
  • potential
    ÀáÀçÇÏ´Â
  • contact potential
    Á¢ÃË ÀüÀ§Â÷
  • electric potential
    ˟ˤ
  • magnetic potential
    ÀÚÀ§
  • market potential
    ½ÃÀåÀÇ ÀáÀç ´É·Â
  • potential
    °¡´ÉÇÑ;°¡´É¼º;ÀüÀ§ÀÇ;°¡´É¹ýÀÇ;°¡´É¼º;Àá¼¼;ÀáÀç·Â;ÀüÀ§;°¡´É¹ý 1
  • potential sovereighty
    ÀáÀç ÁÖ±Ç
  • potential transformer
    °è±â¿ëº¯¾Ð±â
  • all the time
    ±×µ¿¾È Á×,(¹Ì)¾ðÁ¦³ª
  • any time
    ¾ðÁ¦µçÁö
  • at a time
    Çѹø¿¡,µ¿½Ã¿¡
  • at any time
    ¾ðÁ¦¶óµµ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á